In 2018, a Chinese Biophysicist Announced He Had Gene-Edited Twin Girls Using CRISPR. The Scientific Consensus Is that What He Actually Did Was Something Else

Why It Matters

The case demonstrated that premature, poorly governed human germline editing can produce unknown health risks and erode public trust, prompting tighter global regulation of gene‑editing technologies.

Key Takeaways

• He edited CCR5 but created novel, untested deletions
• Mosaicism left edited and unedited cells throughout twins
• Off‑target cuts introduced unknown genetic changes
• Existing IVF methods could have prevented HIV risk safely
• The case spurred stricter global guidelines on germline editing

Pulse Analysis

The 2018 announcement by He Jiankui shocked the biotech world: a self‑proclaimed breakthrough that claimed to give two newborns resistance to HIV using CRISPR‑Cas9. Within days, leading scientists debunked the claim, revealing that the twins carried novel CCR5 deletions rather than the well‑studied Δ32 variant, and that the edits were unevenly distributed across their tissues. Off‑target mutations further clouded the safety profile, turning what was billed as a medical miracle into a cautionary tale of scientific overreach.

Beyond the technical flaws, the experiment ignored established reproductive safeguards. Standard sperm‑washing and antiretroviral therapy already reduce vertical HIV transmission to near zero, rendering the risky germline intervention unnecessary. The Chinese authorities responded swiftly, placing He under house arrest, convicting him of illegal medical practice, and imposing a three‑year prison term plus a fine of about $420,000. Since his 2022 release, He has attempted a low‑profile return to gene‑therapy research, but visa revocations and professional bans underscore the lingering stigma.

The fallout reshaped the global governance of human genome editing. The U.S. National Academies, the UK Royal Society, and the World Health Organization issued comprehensive frameworks that demand robust safety data, transparent oversight, and clear medical justification before any heritable editing can proceed. These guidelines now serve as the benchmark for future proposals, reinforcing a consensus that germline interventions must be scientifically sound and ethically defensible before crossing the line from laboratory curiosity to clinical reality.